|Evotec AG -- USA Stock|| |
USD 20.35 0.00 0.00%
Member of the Supervisory Board
Age: 63 Executive Since 2014 Ph.D
49 40 5 60 81 0 http://www.evotec.com
Paul Linus Herrling, Ph.D., was Member of the Supervisory Board at Evotec AG from June 17, 2014 till 2017. He was Member of the Remuneration and Nomination Committee at the Company. He is former head of global research of Novartis Pharma AG. He is Chairman of the Board at Novartis Institute for Tropical Disease Ltd. Member of Board of Novarits Institute for Functional Genomics La Jolla and Novarits International Pharmaceuticals, Hamilton. He is also Vice President of Eidgenossische Technische Hochschule.
The company has return on total asset (ROA)
of 4.56 %
which means that it generated profit of $4.56 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE)
of 11.13 %
meaning that it generated $11.13 on every $100 dollars invested by stockholders.
The company has accumulated 213.13 M in total debt with debt to equity ratio (D/E) of 53.9 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Evotec AG has Current Ratio of 0.68 indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due.
Evotec AG provides drug discovery solutions to the pharmaceutical and biotechnology companies, academic institutions, and foundations and not-for-profit organizations worldwide. Evotec AG was founded in 1993 and is headquartered in Hamburg, Germany. Evotec AG is traded on OTC Market in USA.Evotec AG (EVOTF) is traded on OTC Market in USA. It is located in Manfred Eigen Campus and employs 1,238 people.